One Charles Private Wealth Services LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

One Charles Private Wealth Services LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 483 shares of the medical research company’s stock, valued at approximately $244,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of TMO. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Thermo Fisher Scientific during the first quarter worth $26,000. Cullen Frost Bankers Inc. increased its holdings in Thermo Fisher Scientific by 2.8% during the first quarter. Cullen Frost Bankers Inc. now owns 9,352 shares of the medical research company’s stock worth $4,268,000 after buying an additional 255 shares during the last quarter. Unigestion Holding SA increased its holdings in Thermo Fisher Scientific by 46.1% during the first quarter. Unigestion Holding SA now owns 3,161 shares of the medical research company’s stock worth $1,443,000 after buying an additional 997 shares during the last quarter. Avidian Wealth Solutions LLC boosted its position in Thermo Fisher Scientific by 5.8% during the first quarter. Avidian Wealth Solutions LLC now owns 1,891 shares of the medical research company’s stock worth $863,000 after purchasing an additional 103 shares during the period. Finally, Donaldson Capital Management LLC boosted its position in Thermo Fisher Scientific by 3.5% during the first quarter. Donaldson Capital Management LLC now owns 1,478 shares of the medical research company’s stock worth $674,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 85.50% of the company’s stock.

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 572 shares of the stock in a transaction that occurred on Friday, July 30th. The stock was sold at an average price of $536.54, for a total transaction of $306,900.88. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 4th. The stock was sold at an average price of $539.05, for a total value of $5,390,500.00. The disclosure for this sale can be found here. Corporate insiders own 0.44% of the company’s stock.

NYSE TMO traded down $2.07 during trading on Wednesday, hitting $560.33. 1,459 shares of the company’s stock were exchanged, compared to its average volume of 1,587,995. The company has a current ratio of 2.78, a quick ratio of 2.11 and a debt-to-equity ratio of 0.51. The company has a market cap of $220.44 billion, a PE ratio of 26.07, a P/E/G ratio of 1.33 and a beta of 0.74. Thermo Fisher Scientific Inc. has a fifty-two week low of $412.80 and a fifty-two week high of $575.63. The stock’s 50 day moving average price is $542.01 and its two-hundred day moving average price is $494.08.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 28th. The medical research company reported $5.60 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $5.51 by $0.09. Thermo Fisher Scientific had a return on equity of 29.43% and a net margin of 22.47%. Analysts forecast that Thermo Fisher Scientific Inc. will post 22.07 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 15th. Investors of record on Wednesday, September 15th will be issued a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.19%. The ex-dividend date of this dividend is Tuesday, September 14th. Thermo Fisher Scientific’s payout ratio is presently 5.32%.

A number of equities analysts have commented on TMO shares. Argus lifted their price objective on shares of Thermo Fisher Scientific from $530.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, August 4th. KeyCorp lifted their price objective on shares of Thermo Fisher Scientific from $520.00 to $555.00 and gave the stock an “overweight” rating in a research report on Monday, July 12th. SVB Leerink reaffirmed an “outperform” rating on shares of Thermo Fisher Scientific in a research report on Monday, July 19th. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “hold” rating to a “strong sell” rating and set a $491.00 target price for the company. in a research report on Monday, July 12th. Finally, Benchmark initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, July 16th. They issued a “buy” rating and a $580.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $547.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Further Reading: How does a reverse stock split work?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.